Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $10.2 million.

  • Exagen's Non-Current Assets rose 2716.2% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 12.03%. This contributed to the annual value of $8.2 million for FY2024, which is 954.63% down from last year.
  • According to the latest figures from Q3 2025, Exagen's Non-Current Assets is $10.2 million, which was up 2716.2% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Non-Current Assets ranged from a high of $19.5 million in Q3 2022 and a low of $7.8 million during Q2 2025
  • Moreover, its 5-year median value for Non-Current Assets was $9.4 million (2021), whereas its average is $11.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 12578.19% in 2022, then tumbled by 3847.57% in 2023.
  • Over the past 5 years, Exagen's Non-Current Assets (Quarter) stood at $10.7 million in 2021, then increased by 27.07% to $13.6 million in 2022, then tumbled by 33.12% to $9.1 million in 2023, then dropped by 9.55% to $8.2 million in 2024, then rose by 24.29% to $10.2 million in 2025.
  • Its Non-Current Assets stands at $10.2 million for Q3 2025, versus $7.8 million for Q2 2025 and $7.8 million for Q1 2025.